Producer
Top Glove Corporation
1
Inputs supplied
1
Goods downstream
1
Facilities
0
Stories
What they make
1 input Top Glove Corporation supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something Top Glove Corporation makes — pick one to see the full supply chain.
What else they do
Business segments
The company's full revenue map — where this supply-chain role fits within their broader business.
Nitrile (NBR) Examination Gloves
50%Natural Rubber Latex Gloves
38%Surgical Gloves & Sterilization (Aspion)
10%Non-Glove Products
2%
Intelligence
What's known
Sourced claims about this company's role in supply chains — chokepoints, concentration, incidents, dual-use connections.
Did you know2026
The Strait of Hormuz directly controls the price of hospital examination gloves. Nitrile gloves are manufactured from nitrile butadiene rubber (NBR) latex — a synthetic polymer derived from butadiene (a naphtha cracking byproduct) and acrylonitrile (derived from propylene). When Iran-Israel hostilities caused the Strait of Hormuz to close to normal traffic in 2025, butadiene and acrylonitrile prices surged approximately 70%. Top Glove confirmed it is raising nitrile glove prices by US$7–9 per 1,000 pieces in direct response. A smaller Malaysian competitor (WRP) was forced to wind down operations entirely under the same cost pressure. Hospital procurement teams, epidemiologists, and emergency planners focused on pandemic preparedness typically do not model Middle East petroleum disruptions as a medical PPE supply chain risk — but they are the same supply chain.
The Star (Malaysia) ↗Chokepoint2025
US tariffs on Chinese glove imports (rising to 100% in 2026) have redirected US medical glove procurement toward Malaysia: Malaysia's share of US disposable glove imports reached 67.5% in the first half of 2025, up from a more balanced multi-country distribution. China's share collapsed from 38.9% to 2.8% over the same period. Top Glove is the dominant supplier within that Malaysian flow. The US health system has effectively re-concentrated its medical glove supply chain into a single geography as a direct result of trade policy — replicating the pre-COVID concentration risk that the pandemic exposed, now in a different country. Any future CBP Section 307 enforcement action against a Malaysian manufacturer, any Malaysian labor disruption, or any Southeast Asian natural disaster would now transmit immediately to US hospital supply chains with limited diversification options.
Nikkei Asia ↗Origin2025
Top Glove was founded in 1991 by Tan Sri Lim Wee Chai, whose family had roots in Malaysian rubber plantations and latex trading. The company listed on Bursa Malaysia in 2001 and grew to command ~26% of global rubber glove market share by 2021 — 100 billion pieces/year from 50 factories. The COVID-19 pandemic was a singular economic event: Q2 FY2021 produced RM2.4 billion net profit in a single quarter (vs. ~RM100M pre-pandemic), briefly making Top Glove the second-largest listed company in Malaysia by market cap. What followed was equally extreme: an 86% revenue collapse from FY2021 to FY2023, a RM927 million net loss in FY2023, factory utilization falling to 33%, zero dividends, director salary cuts, and the closure of all China and Vietnam operations. A US CBP forced labor Finding (2020–2021) added RM300M in worker housing investments and US$36M in remediation payments.
Top Glove Corporation Berhad ↗